Scarica l'app Stockscreener
4.90
15.84%
0.67
Dopo l'orario di chiusura:
4.84
-0.06
-1.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$4.23
Aprire:
$4.27
Volume 24 ore:
14.65M
Relative Volume:
5.64
Capitalizzazione di mercato:
$530.44M
Reddito:
$409.00K
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-2.9878
EPS:
-1.64
Flusso di cassa netto:
$-71.49M
1 W Prestazione:
-36.45%
1M Prestazione:
-7.55%
6M Prestazione:
-31.08%
1 anno Prestazione:
-27.30%
Intervallo 1D:
$4.27
$5.00
Intervallo di 1 settimana:
$2.90
$5.00
Portata 52W:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Nome
Altimmune Inc
Settore
Industria
Telefono
(240) 654-1450
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Confronta ALT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
4.90 | 530.44M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-04-29 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-24 | Iniziato | Goldman | Neutral |
| 2023-03-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-11 | Iniziato | Guggenheim | Buy |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-11-12 | Reiterato | B. Riley Securities | Buy |
| 2020-09-25 | Iniziato | B. Riley FBR | Buy |
| 2020-08-14 | Iniziato | Evercore ISI | Outperform |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-02-24 | Ripresa | ROTH Capital | Buy |
| 2019-07-19 | Iniziato | ROTH Capital | Buy |
| 2017-10-09 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune Announces Multiple Presentations at Upcoming American - GuruFocus
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions - The Manila Times
Breakthrough GLP-1/Glucagon Drug Pemvidutide Reveals Multiple Cardiometabolic Benefits in New Clinical Data - Stock Titan
Kalkine : Altimmune’s Role in NASDAQ Composite Amid Biotech Sector Momentum - Kalkine Media
Altimmune, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
Two Sigma Advisers LP Sells 22,700 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Nuveen Asset Management LLC Has $1.56 Million Stock Position in Altimmune, Inc. (NASDAQ:ALT) - Defense World
BNP Paribas Financial Markets Sells 33,984 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Stifel analysts reaffirm Altimmune stock rating with $18 price target By Investing.com - Investing.com South Africa
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha
Stifel analysts reaffirm Altimmune stock rating with $18 price target - Investing.com India
Altimmune, Inc. (NASDAQ:ALT) Shares Bought by ProShare Advisors LLC - Defense World
Altimmune, Inc. (NASDAQ:ALT) Stock Holdings Increased by Millennium Management LLC - Defense World
Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire
Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. (NASDAQ:ALT) Shares Bought by Deutsche Bank AG - Defense World
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com India
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook - Investing.com
FY2029 EPS Estimate for Altimmune Decreased by Analyst - Defense World
Wall Street Zen Upgrades Altimmune (NASDAQ:ALT) to “Hold” - Defense World
ALT Hosts Virtual Meeting to Discuss Strategic Developments | ALT Stock News - GuruFocus
Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Northern Trust Corp - Defense World
Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential - MSN
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com
Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On? - Benzinga
Altimmune begins phase 2 trial for AUD treatment By Investing.com - Investing.com South Africa
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluati - GuruFocus
Altimmune (ALT) Begins Phase 2 Trial for Pemvidutide in Treating Alcohol Use Disorder | ALT Stock News - GuruFocus
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder - marketscreener.com
Altimmune begins phase 2 trial for AUD treatment - Investing.com
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times
Breakthrough AUD Drug Enters Phase 2 Trial: New Hope for 28 Million US Patients With Alcohol Use Disorder - Stock Titan
HC Wainwright Has Strong Forecast for Altimmune Q2 Earnings - Defense World
William Blair Estimates Altimmune’s Q2 Earnings (NASDAQ:ALT) - Defense World
Price T Rowe Associates Inc. MD Acquires 4,158 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
B. Riley Issues Positive Estimate for Altimmune Earnings - Defense World
(ALT) Proactive Strategies - news.stocktradersdaily.com
Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN
Baird Financial Group Inc. Takes Position in Altimmune, Inc. (NASDAQ:ALT) - The AM Reporter
Stifel Financial Corp Sells 4,649 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey
Voya Investment Management LLC Decreases Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN
Piper Sandler maintains Altimmune stock with $25 target - Investing.com Australia
Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria
Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus
Altimmune to Participate at Two Upcoming Investor Conferences | ALT Stock News - GuruFocus
Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times
Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up - Stock Titan
Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks
Altimmune Inc Azioni (ALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Altimmune Inc Azioni (ALT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):